Summary & Overview
HCPCS J9051: Bortezomib (maia) Injection, 0.1 mg
HCPCS Level II code J9051 designates the drug product bortezomib (maia), billed per 0.1 mg unit and flagged as not therapeutically equivalent to J9041. As a parenteral antineoplastic agent, this code is used when documenting and billing the medication component of chemotherapy regimens in outpatient infusion settings. Nationally, accurate use of J9051 matters for claims consistency, formulary differentiation, and monitoring utilization of branded or non-equivalent drug products.
Key payers discussed include Aetna, Blue Cross Blue Shield, Cigna, UnitedHealthcare, and Medicare. The publication provides national benchmarks and clarifies clinical context for billing the medication itself rather than the infusion procedure. Readers will find: a concise description of the code and its clinical use; guidance on typical sites of service where J9051 is billed; common modifiers and payer considerations summarized; and pointers to where related coding elements and diagnoses would be applied. The content is intended for billing managers, revenue cycle staff, and policy analysts seeking a focused reference on J9051 billing nuances and payer coverage patterns at a national level.
Billing Code Overview
HCPCS Level II code J9051 describes the injection of bortezomib (maia), specifically noted as not therapeutically equivalent to J9041, with a billing unit of 0.1 mg. This code represents a parenteral antineoplastic medication preparation and administration item rather than the administration procedure itself.
Service type: Chemotherapy drug administration / Antineoplastic agent
Typical site of service: Hospital outpatient infusion center, physician office infusion suite, or other outpatient infusion settings
Data not available in the input for associated taxonomies, ICD-10 diagnoses, and related codes.
Clinical & Coding Specifications
Clinical Context
A typical patient is an adult with multiple myeloma or mantle cell lymphoma receiving parenteral proteasome inhibitor therapy. The patient presents to an oncology infusion center or hospital outpatient infusion clinic for administration of J9051 (bortezomib, 0.1 mg). Pre-infusion assessment includes review of recent labs (CBC, CMP), baseline neurologic and pulmonary exam, verification of concurrent medications (especially anticoagulants and neuropathy‑associated drugs), and confirmation of the chemotherapy regimen and cycle number. Vascular access is established via peripheral IV or implanted port. Pharmacy compounds the appropriate bortezomib dose derived from the patient’s body surface area or flat dosing per regimen and prepares the J9051 product according to manufacturer and institutional protocols. Nursing performs time‑in/time‑out, documents lot number and expiration, administers the injection subcutaneously or intravenously per protocol, monitors for acute infusion reactions for the specified observation period, and documents site of administration, patient tolerance, and any interventions. Follow-up includes scheduling subsequent cycles, supportive medications (antiemetics, antiviral prophylaxis), and interval monitoring for hematologic toxicity and peripheral neuropathy.
Coding Specifications
| Modifier | Description | When to Use |
|---|---|---|
00 | No modifier applicable |